Temozolomide vs Radiotherapy for Low-Grade Glioma Shows Equal Survival Outcomes
A mature phase III trial finds no survival difference between chemotherapy and radiotherapy as first-line treatment for low-grade glioma.
Summary
This large randomized trial compared two standard treatments for low-grade brain tumors (gliomas) in 478 patients: chemotherapy with temozolomide versus radiotherapy. After long follow-up, neither treatment was superior for survival overall. However, when tumors were reclassified using modern molecular criteria, important differences emerged. Patients with IDH-wildtype tumors — a more aggressive subtype — actually lived longer with temozolomide than radiotherapy. For IDH-mutant tumors, outcomes were similar regardless of treatment. The study also found that being older than 40 was not necessarily a worse prognostic sign once molecular classification was applied, challenging a long-held assumption. These findings reinforce the push toward molecularly tailored treatment planning in neuro-oncology.
Detailed Summary
Low-grade gliomas (WHO grade 2 brain tumors) are among the most challenging cancers to manage because patients often survive for years or decades, making long-term treatment toxicity a central concern. Choosing between radiotherapy and chemotherapy as a first intervention has long been debated, with no clear consensus on which approach preserves quality of life and survival better.
This mature, multicenter phase III trial (EORTC 22033-26033) randomly assigned 478 high-risk, WHO grade 2 glioma patients to either standard radiotherapy (28 × 1.8 Gy) or dose-dense temozolomide (75 mg/m² daily for 21 of every 28 days, up to 12 cycles). The trial reached long-term follow-up, allowing for meaningful survival analyses.
Overall, no significant difference in progression-free survival or overall survival was found between the two arms. However, post hoc molecular reclassification using 2021 WHO criteria on 351 analyzable tumor samples revealed clinically important subgroup distinctions. IDH-mutant astrocytomas showed similar median OS of 6.6–6.7 years regardless of treatment. IDH-mutant oligodendrogliomas had excellent outcomes exceeding 12 years in both arms. Strikingly, the 64 IDH-wildtype tumors showed a survival benefit favoring temozolomide (4.7 vs. 2.5 years; HR 0.47, p=0.0068), a biologically aggressive subgroup often resembling glioblastoma.
The trial also challenged the conventional view that age under 40 confers a survival advantage, finding that patients aged 40 or older actually fared better once tumors were molecularly stratified — suggesting age alone is an unreliable prognostic marker.
Importantly, combined chemoradiotherapy — now standard of care for IDH-mutant astrocytoma — was not tested here. The results underscore that single-modality decisions must be guided by molecular tumor profiling. As novel therapies emerge, individualized treatment strategies based on pathologic and molecular recurrence-risk profiles will be essential.
Key Findings
- No significant difference in overall or progression-free survival between temozolomide and radiotherapy in low-grade glioma overall.
- IDH-wildtype tumors showed markedly better survival with temozolomide vs radiotherapy (4.7 vs 2.5 years; HR 0.47, p=0.0068).
- IDH-mutant oligodendroglioma patients had exceptional survival exceeding 12 years with either treatment.
- Age over 40 was not a negative prognostic factor when tumors were molecularly classified, challenging current assumptions.
- Molecular subtyping via 2021 WHO criteria is critical for treatment decisions, as aggregate results obscure subgroup differences.
Methodology
Randomized phase III trial enrolling 478 patients with clinically high-risk WHO grade 2 glioma across multiple international centers. Patients were assigned to radiotherapy (50.4 Gy in 28 fractions) or dose-dense temozolomide (75 mg/m² daily, 21/28-day cycles, up to 12 cycles). Molecular reclassification per 2021 WHO criteria was performed post hoc on 73% of analyzable tumor tissue samples.
Study Limitations
The molecular subgroup analyses were post hoc and not pre-specified, limiting the strength of subgroup conclusions. Only 73% of patients had analyzable tissue for molecular reclassification, introducing potential selection bias. The summary is based on the abstract only, as the full text was not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: